NAOV Stock: Why It Substantially Increased Today

By Amit Chowdhry ● Oct 11, 2021
  • The stock price of NanoVibronix, Inc., (NASDAQ: NAOV) increased by over 25% during intraday today. This is why it happened.

The stock price of NanoVibronix, Inc., (NASDAQ: NAOV) – a healthcare device company that produces the UroShield and PainShield Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices – increased by over 25% during today. Investors are responding positively to NanoVibronix announcing positive results from a randomized, double-blind study conducted at Birmingham Orthopedic and Sports Specialists in Birmingham, Alabama.

The clinicians at Birmingham Orthopedic and Sports Specialists recently conducted a randomized, double-blind study to evaluate the safety and effectiveness of the NanoVibronix PainShield. And the patients in the study were being treated by an orthopedic surgeon for lateral epicondylitis, more commonly known as tennis elbow, a swelling or tearing of the tendons in the arm. 

It is characterized by a pain or ache on the outside of the arm where the forearm meets the elbow. And all patients in the study had symptoms of pain and point tenderness at the beginning of the study and had been following customary treatment guidance – which failed to provide pain relief. Conversely – at the conclusion of the study – 91% of the patients in the PainShield treatment group had complete or partial resolution of symptoms. The patients used PainShield in conjunction with over-the-counter medication, as needed, but without the benefit of opioid-based prescription medication.

KEY QUOTES:

“Results of the Birmingham study further reinforce that PainShield is safe, easy-to-use and highly effective in treating soft tissue pain. Patients in the study who wore our device reported marked reduction in pain and when combined with over-the-counter, anti-inflammatory medications, those same patients reported a complete resolution of symptoms within 10 days.”

— Brian Murphy, CEO of Nanovibronix

“Patient outcomes were markedly improved with the use of PainShield and importantly, no patients returned with signs or symptoms of an exacerbation. Most encouraging are the results we were able to achieve for our patients without the use of prescription opioid medications, which can often lead to prolonged use and addiction.”

— Dr. David Lemak, MD, Lead Investigator of the Birmingham Study

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.